About this journal
Aims and scope
*Please note that HIV Research & Clinical Practice converted to a full Open Access journal from Volume 22 (2022) and archive content will be made free to access. Please note, from 2022 the Print ISSN is not in active use as this journal is no longer published in print.
HIV Research and Clinical Practice is devoted to presenting information on the latest developments in clinical and translational research related to HIV, as well as advances in science and care that directly affect clinical practice. This journal enables readers to obtain the most up-to-date, innovative research from around the world.
In an era of increasingly well tolerated antiretroviral therapy (ART) much focus of research in the HIV field is examining the complex interplay of inflammation, ageing, and the development of chronic comorbidities in people with HIV. HIV Research and Clinical Practice aims to provide an authoritative forum for this area, with a focus on impactful clinical and translational research, as well as advances in clinical care. This international, peer-reviewed journal also intends to publish research undertaken with strong implementation science principles , whether supporting testing and treatment for HIV, best practices in prevention, or acute or chronic aspects of HIV care. The overarching principle is to improve quality of care, and quality of life, for all people with HIV, as well as those at risk of HIV acquisition also.
As access to successful HIV treatment and care improves globally, an increasing emphasis on quality of life and long-term outcomes can emerge. Aspects of holistic care based in HIV may improve, strengthen, and support healthcare systems and enable better provision of care for all. HIV has much to teach us about the contributions of a chronic pro-inflammatory infection to frailty, cancer, and renal, bone, neurocognitive, cardiovascular disease, amongst others. As biomarkers and targets for interventions are established in the context of HIV, so we hope there may be benefits for all those who age, with or without the added burden of HIV. As we understand more about healthcare systems and how heightened surveillance of people with HIV must lead to improved quality and length of life, so we hope this knowledge may also have benefits for all.
HIV Research and Clinical Practice welcomes authors and researchers to submit their work on:
• Therapeutic clinical trials, diagnostic clinical trials, or preventative clinical trials; including reports of clinical and translational research, and meta-analysis
• Observational studies relevant to HIV research and clinical practice
• Pilot studies on HIV clinical and translational research
• Studies based in implementation science methodology
• Methodological papers relating to HIV clinical care
• Translational studies describing research becoming best clinical practice
• Quality of life and pharmacoeconomic evaluations relating to HIV clinical care
• Socio-behavioural research related to improving the quality of life for people with HIV
• Expert consensus statements relevant to advances in clinical care and research
The journal adopts the UNAIDS terminology guidelines, all authors need to ensure their submission uses the preferred terminology as described in the following: https://www.unaids.org/sites/default/files/media_asset/2015_terminology_guidelines_en.pdf
HIV Research & Clinical Practice is proud to endorse the People First Charter, promoting person-first HIV & Sexual Health language. Person-first language simply puts people before their condition, recognising that people are people, and not defined by their condition. In HIV care we should avoid terms like ‘HIV-infected people’ and use ‘people with HIV’. Please consult their recommended terminology for research and publications related to HIV here when preparing your submission for the journal.
HIV Research & Clinical Practice accepts Research Articles, Reviews, Patient Perspectives, Brief Reports, Case Reports, Meeting Reports, Comments, Methods, Data Notes, Letters to the Editor and Editorials for publication.
Author Benefits
The prestigious and experienced members of our international Editorial Board will guide you from submission to publication.
Our Author Services page provides you with tips and tricks to promote your research on social media and through your network. This includes 50 free e-prints to share with whomever you choose.
We have enabled easy tracking to measure the impact your paper makes with the help of My Authored Works.
Journal metrics
Usage
- 68K annual downloads/views
Citation metrics
- 1.7 (2023) Impact Factor
- 1.7 (2023) 5 year IF
- 2.9 (2023) CiteScore (Scopus)
- 0.507 (2023) SNIP
- 0.616 (2023) SJR
Speed/acceptance
- 30 days avg. from submission to first decision
- 41 days avg. from submission to first post-review decision
- 15 days avg. from acceptance to online publication
- 34% acceptance rate
Understanding and using journal metrics
Journal metrics can be a useful tool for readers, as well as for authors who are deciding where to submit their next manuscript for publication. However, any one metric only tells a part of the story of a journal’s quality and impact. Each metric has its limitations which means that it should never be considered in isolation, and metrics should be used to support and not replace qualitative review.
We strongly recommend that you always use a number of metrics, alongside other qualitative factors such as a journal’s aims & scope, its readership, and a review of past content published in the journal. In addition, a single article should always be assessed on its own merits and never based on the metrics of the journal it was published in.
For more details, please read the Author Services guide to understanding journal metrics.
Journal metrics in brief
Usage and acceptance rate data above are for the last full calendar year and are updated annually in February. Speed data is updated every six months, based on the prior six months. Citation metrics are updated annually mid-year. Please note that some journals do not display all of the following metrics (find out why).
- Usage: the total number of times articles in the journal were viewed by users of Taylor & Francis Online in the previous calendar year, rounded to the nearest thousand.
Citation Metrics
- Impact Factor*: the average number of citations received by articles published in the journal within a two-year window. Only journals in the Clarivate Science Citation Index Expanded (SCIE), Social Sciences Citation Index (SSCI), Arts and Humanities Citation Index (AHCI) and the Emerging Sources Citation Index (ESCI) have an Impact Factor.
- Impact Factor Best Quartile*: the journal’s highest subject category ranking in the Journal Citation Reports. Q1 = 25% of journals with the highest Impact Factors.
- 5 Year Impact Factor*: the average number of citations received by articles in the journal within a five-year window.
- CiteScore (Scopus)†: the average number of citations received by articles in the journal over a four-year period.
- CiteScore Best Quartile†: the journal’s highest CiteScore ranking in a Scopus subject category. Q1 = 25% of journals with the highest CiteScores.
- SNIP (Source Normalized Impact per Paper): the number of citations per paper in the journal, divided by citation potential in the field.
- SJR (Scimago Journal Rank): Average number of (weighted) citations in one year, divided by the number of articles published in the journal in the previous three years.
Speed/acceptance
- From submission to first decision: the average (median) number of days for a manuscript submitted to the journal to receive a first decision. Based on manuscripts receiving a first decision in the last six months.
- From submission to first post-review decision: the average (median) number of days for a manuscript submitted to the journal to receive a first decision if it is sent out for peer review. Based on manuscripts receiving a post-review first decision in the last six months.
- From acceptance to online publication: the average (median) number of days from acceptance of a manuscript to online publication of the Version of Record. Based on articles published in the last six months.
- Acceptance rate: articles accepted for publication by the journal in the previous calendar year as percentage of all papers receiving a final decision.
For more details on the data above, please read the Author Services guide to understanding journal metrics.
*Copyright: Journal Citation Reports®, Clarivate Analytics
†Copyright: CiteScore™, Scopus
Editorial board
Editor in Chief
Tristan Barber, (Royal Free Hospital, London, UK)
Editorial Board
Judith A. Aberg, (Icahn School of Medicine at Mount Sinai, NY, USA)
Joseph Cherabie, (Division of Infectious Diseases, Washington University St. Louis; CDC Midwest 2B Capacity Building Assistance Program; St. Louis STI/ HIV Prevention Training Center, St Louis, MO, USA)
Karine Dubé, (Division of Infectious Diseases and Global Public Health, University of California San Diego (UCSD) School of Medicine, CA, USA)
Sidd Kogilwaimath, (Division of Infectious Diseases and Geographic Medicine, UT Southwestern Medical Center, Dallas, TX, USA)
Carlee Moser, (Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, MA, USA)
Takashi Muramatsu, (Department of Laboratory Medicine, Tokyo Medical University Hospital, Tokyo, Japan)
Hideta Nakamura, (Division of Infectious, Respiratory, and Digestive Medicine, University of the Ryukyus Graduate School of Medicine, Okinawa, Japan)
Silvia Nozza, (Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy)
Oana Sandulescu, (Carol Davila University of Medicine and Pharmacy and National Institute for Infectious Diseases "Prof.Dr. Matei Bals", Bucharest, Romania)
Jochen Schneider, (Technical University of Munich, Munich, Germany)
Agata Skrzat-Klapaczyńska, (Department of Infectious Diseases for Adults, Medical University of Warsaw and Hospital for Infectious Diseases, Warsaw, Poland)
Colette Smith, (Institute of Global Health, University College London, London, UK)
Ricardo Roberto de Souza Fonseca, (Federal University of Pará, Belém, Brazil)
Nnakelu Eriobu, (Institute of Human Virology Nigeria, Abuja, Nigeria)
Onu Adamu (Garki Hospital, Abuja, Nigeria)
Founding Editor-in-Chief: HIV Clinical Trials
Maurice J Staquet
Emeritus Editors
Caroline A. Sabin, (Institute for Global Health, University College London, London, UK)
Alain Lafeuillade, (Institute of Human Virology, University of Maryland School of Medicine, MD, USA)
Jordan E. Lake, (McGovern Medical School, University of Texas, TX, USA)
David Hardy, (Division of Infectious Diseases, Johns Hopkins University School of Medicine, MD, USA)
Abstracting and indexing
HIV Research & Clinical Practice is indexed by the following services:
- Current Contents: Clinical Medicine
- DOAJ
- EMBASE
- Elsevier BIOBASE
- ISI Alerting Services
- MEDLINE
- PubMed
- Science Citation Index
- Scopus
Open access
HIV Research & Clinical Practice is an open access journal and only publishes open access articles. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research.
Why choose open access?
- Increase the discoverability and readership of your article
- Make an impact and reach new readers, not just those with easy access to a research library
- Freely share your work with anyone, anywhere
- Comply with funding mandates and meet the requirements of your institution, employer or funder
- Rigorous peer review for every open access article
Article Publishing Charges (APC)
To publish open access in this journal you may be asked to pay an Article Publishing Charge (APC). You may be able to publish your article at no cost to yourself or with a reduced APC if your institution or research funder has an open access agreement or membership with Taylor & Francis. Discounts and waivers may also be available for researchers in selected countries when publishing in open access journals.
Use our APC finder to calculate your article publishing charge
News, offers and calls for papers
Continuous publication
Currently known as:
- HIV Research & Clinical Practice (2019 - current)
Formerly known as
- HIV Clinical Trials (2000 - 2018)
Advertising information
Would you like to advertise in HIV Research & Clinical Practice?
Reach an engaged target audience and position your brand alongside authoritative peer-reviewed research by advertising in HIV Research & Clinical Practice.
Taylor & Francis make every effort to ensure the accuracy of all the information (the "Content") contained in our publications. However, Taylor & Francis, our agents (including the editor, any member of the editorial team or editorial board, and any guest editors), and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor & Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to, or arising out of the use of the Content. Terms & Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions .
Ready to submit?
Start a new submission or continue a submission in progress
Go to submission site (link opens in a new window) Instructions for authors